Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands

Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam

(2017) Marc Xipell et al.   Future Microbiology

Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers

(2017) Tommaso Giani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L

(2017) Senthil Natesan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa

(2017) Pablo A Fraile-Ribot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates

(2016) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

(2016) Juan José Castón et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

(2016) David van Duin et al.   CLINICAL INFECTIOUS DISEASES

Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections

(2016) Matteo Bassetti et al.   Expert Review of Anti-Infective Therapy

Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies

(2016) Silvia Gómez-Zorrilla et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration

(2015) Wesley D. Oliver et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

(2015) Joseph Solomkin et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study

(2015) Marta Tato et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia

(2015) Alan J. Xiao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

(2015) Florian M Wagenlehner et al.   LANCET

Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC

(2014) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

(2014) Dilip Nathwani et al.   Antimicrobial Resistance and Infection Control

Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort

(2013) Carmen Peña et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial Resistance and Virulence: a Successful or Deleterious Association in the Bacterial World?

(2013) A. Beceiro et al.   CLINICAL MICROBIOLOGY REVIEWS

Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities

(2012) Bartolomé Moyá et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones

(2012) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AmpG Inactivation Restores Susceptibility of Pan-β-Lactam-Resistant Pseudomonas aeruginosa Clinical Strains

(2011) Laura Zamorano et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Activity of a New Cephalosporin, CXA-101 (FR264205), against  -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients

(2010) B. Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY